As follow-up
of our past publication？[1], we
propose that quinolones (as part of the pyridinone family) are capable to
increase the number of interactions with HIV reverse transcriptase
(RT) or integrase (IN) by adding a halogen in position C-8 of aromatic portion
of the quinolones. This addition could help with the activity of dual
inhibitors of RT and IN. In this work, we add a chlorine atom with the
rationale to identify in the docking simulations a halogen interaction with the
oxygen in the near aminoacids in the binding pockets of RT and IN enzymes.
Our docking studies started with RT and 320 structures. Later, we took 73
structures with good results in docking with RT. The structures that we choose
contain ester or acids groups in C-3 due the structural similarity with groups
in charge to interact with the Mg++ ions in Elvitegravir. In
conclusion, we obtained 14 structures that could occupy the allosteric pocket
of RT and could inhibit the catalytic activity of IN, for this reason could be
dual inhibitors. A major perspective of this work is the synthesis and testing
of the potential dual inhibitors designed.
References
[1]
Cabrera, A., Chávez, D., Huerta, L. and Medina-Franco, J.L. (2018) Molecular Modeling of Potential Dual Inhibitors of HIV Reverse Transcriptase and Integrase. Computational Molecular Bioscience, 8, 1-41. https://doi.org/10.4236/cmb.2018.81001
[2]
Cabrera, A., Chávez, D., Reyes, H., et al. (2015) Crystal Structure of Ethyl 2,4-Dichloroquinoline-3-Carboxylate. Acta Crystallographica, E71, o939.
[3]
Hopkins, A.L., Ren, J., Milton, J., et al. (2004) Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1. Journal of Medicinal Chemistry, 47, 5912-5922. https://doi.org/10.1021/jm040071z
[4]
Medina-Franco, J.L., Martínez-Mayorga, K., Juárez-Gordiano, C. and Castillo, R. (2007) Pyridin-2(1H)-Ones: A Promising Class of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. ChemMedChem, 2, 1141-1147. https://doi.org/10.1002/cmdc.200700054
[5]
Li, A., Ouyang, Y., Wang, Z., et al. (2013) Novel Pyridinone Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with High Potency against NNRTI-Resistant HIV-1 Strains. Journal of Medicinal Chemistry, 56, 3593-3608. https://doi.org/10.1021/jm400102x
[6]
Tang, J., Maddali, K., Dreis, C.D., et al. (2011) N-3 Hydroxylation of Pyrimidine-2,4-Diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase. ACS Medicinal Chemistry Letters, 2, 63-67. https://doi.org/10.1021/ml1002162
[7]
Freeman, G.A., Andrews III, C.W., Hopkins, A.L., et al. (2004) Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2. Journal of Medicinal Chemistry, 47, 5923-5936. https://doi.org/10.1021/jm040072r
[8]
Tang, J., Maddali, K., Pommier, Y., Sham, Y.Y. and Wang, Z. (2010) Scaffold Rearrangement of Dihydroxypyrimidine Inhibitors of HIV Integrase: Docking Model Revisited. Bioorganic and Medicinal Chemistry Letters, 20, 3275-3279. https://doi.org/10.1016/j.bmcl.2010.04.048
[9]
Politzer, P., Murray, J.S. and Clark, T. (2010) Halogen Bonding: An Electrostatically-Driven Highly Directional Noncovalent Interaction. Physical Chemistry Chemical Physics, 12, 7748-7757. https://doi.org/10.1039/c004189k
[10]
AIDSinfo (2018) Understanding HIV/AIDS. Fact Sheets. FDA-Approved HIV Medicines. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines
Mendez-Lucio, O., Naveja, J.J., Vite-Caritino, H., Prieto-Martinez, F.D. and Medina-Franco, J.L. (2013) One Drug for Multiple Targets: A Computational Perspective. Journal of the Mexican Chemical Society, 60, 168-181.
[13]
Himmel, D.M., Das, K., Clark, A.D., et al. (2005) Crystal Structures for HIV-1 Reverse Transcriptase in Complexes with Three Pyridinone Derivatives: A New Class of Non-Nucleoside Inhibitors Effective against a Broad Range of Drug-Resistant Strains. Journal of Medicinal Chemistry, 48, 7582-7591. https://doi.org/10.1021/jm0500323
[14]
Berman, H.M., Westbrook, J., Feng, Z., et al. (2000) The Protein Data Bank. Nucleic Acids Research, 28, 235-242. https://doi.org/10.1093/nar/28.1.235
[15]
Hare, S., Gupta, S.S., Valkov, E., Engelman, A. and Cherepanov, P. (2010) Retroviral Intasome Assembly and Inhibition of DNA Strand Transfer. Nature, 464, 232-236. https://doi.org/10.1038/nature08784
[16]
Molecular Operating Environment (MOE) (2014) Chemical Computing Group Inc., Montreal. https://www.chemcomp.com/
[17]
Krusemark, C.J. (2012) Drug Design: Structure- and Ligand-Based Approaches. The Quarterly Review of Biology, 87, 165.
[18]
Kerns, E.H. and Di, L. (2016) Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. Academic Press, Amsterdam, 31.
[19]
Radi, M., Falciani, C., Contemori, L., et al. (2008) A Multidisciplinary Approach for the Identification of Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: S-DABOCs and DAVPs. ChemMedChem, 3, 573-593. https://doi.org/10.1002/cmdc.200700198
[20]
Medina-Franco, J.L., Rodríguez-Morales, S., Juárez-Gordiano, C., Hernández Campos, A., Jiménez-Barbero, J. and Castillo, R. (2004) Flexible Docking of Pyridinone Derivatives into the Non-Nucleoside Inhibitor Binding Site of HIV-1 Reverse Transcriptase. Bioorganic and Medicinal Chemistry, 12, 6085-6095. https://doi.org/10.1016/j.bmc.2004.09.008
[21]
Medina-Franco, J.L., Rodríguez-Morales, S., Juárez-Gordiano, C., Hernández Campos, A. and Castillo, R. (2004) Docking-Based CoMFA And CoMSIA Studies of Non-Nucleoside Reverse Transcriptase Inhibitors of the Pyridinone Derivative Type. Journal of Computer Aided Molecular Design, 18, 345-360. https://doi.org/10.1023/B:JCAM.0000047816.15514.ab
